Osborne Clarke in Amsterdam has advised the shareholders of Genome Diagnostics B.V. (GenDx), a leading HLA diagnostics company, in the competitive auction process relating to the sale of GenDx to Eurobio Scientific for an amount of €135 million.
The agreement is the final result of an intensive project named Ad Tempus Vitae (ATV), meaning ‘to prolong life’ which on the one hand refers to GenDx’ offering of products and services aimed at prolonging the life of transplant patients and on the other hand also refers to prolonging the life of the GenDx by securing the 18 year old legacy of the founders. The GenDx portfolio will be continued and supported by its existing mature sales and global distributor network.
Eurobio Scientific is a listed French group and is a leader in the field of in-vitro medical diagnostics and life sciences.
The Osborne Clarke team was led by Herke Van Hulst and Wouter Kok and included Casper Schnepper and Nick Staes (Corporate), Job van der Pol, Cees Graafland, Sjoerd Waagmeester and Aram Hovanesjan (Tax), Jim Margry and Rosalie Zwarthoed(Employment), Cars-Jan van Gool and Arlette Peer (Notary), Coen Barneveld Binkhuysen, Gianna Hendriks, Joanne Zaaijer, Romy van Limpt (TMC), Axel van der Staak, Marlinde Klein Ganseij (Banking & Finance), Charlie van der Star and Benthe Janssen (Real Estate).
Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms and the biggest pharma and medical devices companies in the market. Recent notable M&A work from the team in Amsterdam in the life science and healthcare sector includes advising the shareholders of MILabs on the sale to Rigaku Corporation, advising management on the sale of Viroclinics-DDL to Cerba and Terumo Corporation on the acquisition of Quirem Medical.